Greiner Bio-One
keyboard_backspaceBack to Home
Contact
3 à 7 Avenue du Cap Horn
91940 Les Ulis
France
Directeur des Ventes
About us
Greiner Bio-One develops, manufactures and distributes high-quality laboratory products. The company is the technological partner for hospitals, laboratories, universities, research institutes and the diagnostic, pharmaceutical and biotech industries. Greiner Bio-One is divided into three business units: Preanalytics, BioScience and Sterilization. As an Original Equipment Manufacturer (OEM), Greiner Bio-One provides customized design and production solutions for the life science and medical sectors.
Business offer
Greiner Bio-One is one of the leading suppliers of special products for the cultivation and analysis of cell and tissue cultures. Under the brand name CELLSTAR® , we offer cell culture flasks, dishes and plates in a wide variety of formats and surface modifications, so that you will always find exactly the right product for every application and all cell types.
In addition, we have been developing and producing microplates for high-throughput screening for more than 50 years, enabling industry and research to carry out fast and most efficient drug testing. Among other things, Greiner Bio-One was the first manufacturer to introduce a microplate in 1536 well format to the market, setting new standards in terms of automation, performance and cost reduction.
Based on decades of experience in the cryogenic storage of samples, we also offer comprehensive solutions for automated storage systems in biobanks.
Activities
- Technology Supplier
- Genetic Diseases
- Oncology
- Hematology
- Infectiology
- Immunology
- Inflammation
- Target selection & validation
- Gene / protein discovery
- bioinformatics design
- Expression and pathway analysis of target
- quantification of target
- Assay development in in-vitro & in-vivo models
- Research exploratory companion biomarkers
- Preclinical biomarkers
- Mechanism/Function
- Mechanism of action
- Safety
- PK/PD features
- Indication Identification
- Exploratory toxicology
- Drug-Target interaction
- Level of response duration
- Specificity
- Surrogate markers
- Research exploratory Companion biomarkers
- Bioinformatics design
- Bioinformatics prediction & analysis
- Animal biomarkers
- Human biomarkers
- Predictive biomarkers
- Treatment efficacy
- Population stratification
- Risk/benefit profile
- Disease progression / follow-up
- Bioproduction
- Batches production type
- Mammalian
- Insect
- Yeast
- Bacterial
- GLP compliance
- GMP compliance
- Pilot Batches
- Tests
- Optimization
- Scale-Up process
- Process optimization & validation
- Volume
- Preclinical / Tox
- Low volume (< 200 L)
- High volume (200 – 2000 L)
- Very high volume (> 2000 L)
- Commercial
- USP (Scale-Up)
- Cell expansion
- Inoculation
- Low volume containers to Bioreactors
- DSP (Recovery)
- Harvest
- Filtration
- Purification
- Fill & Finish
- Aseptic filling
- Lyophilization
- Batch release
- Storage matter
- Instruction
- Logistic
- Cell cryopreservation
- Controlled-rated freezer
- thaw
- Target cell isolation
- iPS reprogramming
- Differentiated Cell
- Production Cell
- Safety donor-derived therapies
- Target Identification
- Gene / protein discovery
- bioinformatics design
- Expression and pathway analysis of target
- quantification of target
- Assay development in in-vitro & in-vivo models
- Research exploratory companion biomarkers
- Bioproduction/CMC/Analytical Quality Assessment, Quality Control
- Bioproduction
- Scale-Up
- Automated manufacturing
- Automated high throughput microbioreactor system
- Supply chain logistics
- Tracking process
- Monitoring logistics
- Non-GMP pilot batch
- GMP batch
- Cleaning
- CGMP
- Cross contamination
- Sterility
- Deviations
- Quality control
- Contaminants detection
- Safety for gene-edited cells
- Translocation
- anti-nuclease response
- cytokine-independent growth
- Bioproduction GMP
- Vaccine platform type
- Recombinant protein expression
- Synthetic Peptides or oligomers
- Virus-like particles (VLP) and nanoparticle-based carriers
- killed/inactivated virus
- Live attenuated virus
- Viral vector encoding target antigen
- DNA plasmid vaccine
- mRNA vaccine
- Lipid delivery vehicle
- Outer-membrane vesicles (OMV)
- Polysaccharides/ conjugated vaccines
- Other
- Pilot Batches scale
- Process development & optimization
- Scale-Up & Validation
- Comparability characterization protocol
- Manufacturing Volume
- Small volume (< 100 L) adjusted to phase I/II needs: specify volume
- Large volume (100 – 1000 L) adapted for phase III needs
- Final scale up volume (> 1000 L) and validation for manufacturing
- Commercial supply during life cycle management
- USP (Scale-Up)
- DSP (Recovery)
